Dexamethasone-loaded chitosan-based genipin-cross-linked hydrogel for prevention of cisplatin induced ototoxicity in Guinea pig model

Int J Pediatr Otorhinolaryngol. 2019 Jul:122:60-69. doi: 10.1016/j.ijporl.2019.04.003. Epub 2019 Apr 3.

Abstract

Objectives: The aim of this study was to investigate the protective effects of a sustained release form of dexamethasone (dex) loaded chitosan-based genipin-cross-linked hydrogel (CBGCH) in a guinea pig model of cisplatin (CP) induced hearing loss.

Methods: Implantation of CBGCH was made by intratympanic (IT) injection. Ototoxicity was produced by intraperitoneal (IP) single dose of 14 mg/kg CP. Animals were randomly divided into four groups with 6 guinea pigs in each. Group 1 received only IP CP; group 2 received only IT dex-loaded CBGCH injections. Group 3 and group 4 received IP CP, plus IT nondrug CBGCH and IT dex-loaded CBGCH respectively 24 h prior to IP CP injections. Distortion product otoacoustic emissions (DPOAEs) and auditory brainstem response (ABR) measurements were obtained before the treatments and solely ABR measurements were done after 3 and 10 days. The ultrastructural effects were investigated by scanning electron microscopy (SEM) analysis.

Results: The postCP ABR thresholds at 4, 8, 12, 16, 32 kHz frequencies were significantly better in group 4 than groups 1 and 3 (p < 0.05). The comparison of time effective ABR thresholds between groups 1 and 4 and between groups 3 and 4 showed significantly lower ABR thresholds in group 4 (p < 0.05). The SEM analysis showed that stereocilia of inner and outer hair cells were preserved in group 4, almost like group 2, whereas cytotoxic degenerations were noted in groups 1 and 3.

Conclusions: Intratympanic administration of dex-loaded CBGCH has been shown to provide functional and structural protection against CP-induced ototoxicity.

Keywords: Cisplatin; Dexamethasone; Genipin; Guinea pig; Hydrogel; Ototoxicity.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / therapeutic use*
  • Antineoplastic Agents / adverse effects
  • Auditory Threshold / drug effects
  • Biocompatible Materials / therapeutic use
  • Chitosan / therapeutic use
  • Cholagogues and Choleretics / therapeutic use*
  • Cisplatin / adverse effects
  • Delayed-Action Preparations / therapeutic use
  • Dexamethasone / administration & dosage
  • Dexamethasone / therapeutic use*
  • Drug Combinations
  • Evoked Potentials, Auditory, Brain Stem / drug effects
  • Guinea Pigs
  • Hair Cells, Auditory, Inner
  • Hair Cells, Auditory, Outer
  • Hearing Loss / chemically induced
  • Hearing Loss / prevention & control*
  • Hydrogels / therapeutic use
  • Iridoids / therapeutic use*
  • Male
  • Microscopy, Electron, Scanning
  • Otoacoustic Emissions, Spontaneous / drug effects
  • Random Allocation
  • Stereocilia / ultrastructure

Substances

  • Anti-Inflammatory Agents
  • Antineoplastic Agents
  • Biocompatible Materials
  • Cholagogues and Choleretics
  • Delayed-Action Preparations
  • Drug Combinations
  • Hydrogels
  • Iridoids
  • Dexamethasone
  • Chitosan
  • genipin
  • Cisplatin